This may be a good long term investment!
The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics,
aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be
generated per annum from the cellular therapies at an average gross profit of 70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018. By combining surgical revenues with cell therapy revenues, the company believes it has developed a risk mitigated market entry model and a business model poised for sustainable growth.
Beyond the operation of providing a fully equipped and staffed surgical center for
the collection and use of SVFC's with patients, IntelliCell believes there are
additional methods the IntelliCell business model can generate value:
• Licensing its technology for international partners and additional areas of
clinical development. This could include wound care, cardiac, gastrointestinal
(colitis/ileitis), multiple sclerosis and autism to other companies in the
regenerative medicine field.
• Establishment of an SVF cellular tissue bank. IntelliCell will market this
service to liposuction patients in addition to any patient who might want to
store their SVFC's for future use3
• Fees from training and certifying physicians in the use of the IntelliCell
process
